New dosing strategy for MS drug ublituximab under study in 800-Patient trial
NCT ID NCT05877963
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial is testing a modified dosing schedule of ublituximab (BRIUMVI) in 800 people with relapsing multiple sclerosis. The study has three parts: one open-label part to see if the new regimen reduces brain lesions, a placebo-controlled part to measure drug levels, and another open-label part for those who had a poor response to prior anti-CD20 therapy. The goal is to find a safer or more effective way to control MS relapses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ublituximab (BRIUMVI)
What this could lead to
If successful, this could offer a more effective or convenient dosing schedule for ublituximab to control relapsing multiple sclerosis.
What could go wrong
This is a Phase 3 study, but results may not confirm benefit over existing treatments. Infusion-related reactions and other side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
TG Investigational Site
RECRUITINGFort Collins, Colorado, 80528, United States
-
TG Investigational Site
RECRUITINGFarmington, Michigan, 48334, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGBirmingham, Alabama, 35209, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGCullman, Alabama, 35058, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGOrange, California, 92697, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGWashington D.C., District of Columbia, 20007, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGTampa, Florida, 33612, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGSavannah, Georgia, 31406, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGChicago, Illinois, 60612, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGIndianapolis, Indiana, 46256, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGIowa City, Iowa, 52242, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGOverland Park, Kansas, 66212, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGLutherville, Maryland, 21093, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGBoston, Massachusetts, 00002, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGFoxborough, Massachusetts, 02035, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGNorth Worcester, Massachusetts, 01655, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGWellesley, Massachusetts, 02481uni, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGGolden Valley, Minnesota, 55422, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGPlymouth, Minnesota, 55446, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGSt Louis, Missouri, 63131, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGNew York, New York, 10025, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGNew York, New York, 11021, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGRaleigh, North Carolina, 27607, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGCleveland, Ohio, 44195, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGDayton, Ohio, 45417, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGOklahoma City, Oklahoma, 73104, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGGreenville, South Carolina, 29605, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGKnoxville, Tennessee, 37922, United States
-
TG Therapeutics Investigational Trial Site
ACTIVE_NOT_RECRUITINGHouston, Texas, 77030, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGSalt Lake City, Utah, 84103, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGVienna, Virginia, 22182, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGKirkland, Washington, 98034, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGSeattle, Washington, 98109, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGSpokane, Washington, 99208, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGMilwaukee, Wisconsin, 53226, United States
-
TG Therapeutics Investigational Trial Site
RECRUITINGBydgoszcz, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGKatowice, 40-555, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGKatowice, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGKielce, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGKrakow, 31-826, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGLodz, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGOlsztyn, 10-561, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGPoznan, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGWarsaw, 04-141, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGZabrze, Poland
-
TG Therapeutics Investigational Trial Site
RECRUITINGŻory, 44-240, Poland
-
TG Therapeutics Investigational Trial SiteCharlotte
RECRUITINGCharlotte, North Carolina, 28204, United States